Filgrastim-SNDZ Debuts as the First Biosimilar Approved in United States

Journal of Community and Supportive Oncology - United States
doi 10.12788/jcso.0203
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontline Medical Communications, Inc.

Related search

Expanded Access to Cancer Treatments From Conversion to Neutropenia Prophylaxis With Biosimilar Filgrastim-SNDZ

Future Oncology
MedicineCancer ResearchOncology
2017English

FDA-Approved Biosimilar Insulin

Journal of diabetes science and technology
Internal MedicineEndocrinologyBioengineeringBiomedical EngineeringMetabolismDiabetes
2014English

The First Biosimilar Approved for the Treatment of Osteoporosis: Results of a Comparative Pharmacokinetic/Pharmacodynamic Study

Osteoporosis International
MedicineEndocrinologyMetabolismDiabetes
2018English

Quality Comparison of Biosimilar and Copy Filgrastim Products With the Innovator Product

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2018English

Pharmacokinetic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial

Annals of Hematology
MedicineHematology
2010English

Comparison of the Pharmacodynamic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial

Annals of Hematology
MedicineHematology
2010English

Uptake of TBO-Filgrastim in the Outpatient Setting Among Commercially Insured and Medicare Supplemental Populations in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union

JAMA - Journal of the American Medical Association
Medicine
2008English

Analysis of Average Manufacturer Prices of New Drugs Approved in the United States (1990-2012)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy